Amgen’s research site in Burnaby, British Columbia, is developing 3D tissue models using human tonsil tissue and bioprinting technology to predict how the human immune system will react to new drugs. These models aim to identify potential immune responses early in drug development, reducing the risk of clinical trial failures. The team also plans to use bioprinted tissues for antibody discovery, allowing for customized immune responses.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
3D Tissue Models Mimic the Human Immune System to Inform Drug Development
Amgen’s research site in Burnaby, British Columbia, is developing 3D tissue models using human tonsil tissue and bioprinting technology to predict how the human immune system will react to new drugs. These models aim to identify potential immune responses early in drug development, reducing the risk of clinical trial failures. The team also plans to use bioprinted tissues for antibody discovery, allowing for customized immune responses.